{"name": "Virdante Pharmaceuticals",
 "permalink": "virdante-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/virdante-pharmaceuticals",
 "homepage_url": "http://www.virdante.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": 2007,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "info@virdante.com",
 "phone_number": "617-300-8500",
 "description": "",
 "created_at": "Fri Oct 30 02:27:40 UTC 2009",
 "updated_at": "Thu Nov 26 03:01:40 UTC 2009",
 "overview": "\u003Cp\u003EVirdante Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes drugs for autoimmune and inflammatory diseases. It offers antibody and Fc-fusion drugs to treat auto-immune diseases. The company was formerly known as Centaurus Pharmaceuticals and changed its name to Virdante Pharmaceuticals, Inc. in April, 2008. The company was founded in 2007 and is based in Cambridge, Massachusetts.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       42],
      "assets/images/resized/0006/4176/64176v1-max-150x150.jpg"],
     [[250,
       71],
      "assets/images/resized/0006/4176/64176v1-max-250x250.jpg"],
     [[278,
       79],
      "assets/images/resized/0006/4176/64176v1-max-450x450.jpg"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "CEO",
    "person":
     {"first_name": "John",
      "last_name": "Ripple",
      "permalink": "john-ripple",
      "image": null}},
   {"is_past": false,
    "title": "Scientific Founder and Chairman of the Scientific Advisory Board",
    "person":
     {"first_name": "Jeffrey",
      "last_name": "V. Ravetch",
      "permalink": "jeffrey-v-ravetch-2",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$30M",
 "funding_rounds":
  [{"round_code": "a",
    "source_url": "http://onbiovc.com/virdante-pharmaceuticals-inc-series-a-30m/",
    "source_description": "Virdante Pharmaceuticals, Inc.: Series A $30M",
    "raised_amount": 30000000.0,
    "raised_currency_code": "USD",
    "funded_year": 2009,
    "funded_month": 11,
    "funded_day": 25,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "Clarus Ventures",
         "permalink": "clarus-ventures",
         "image":
          {"available_sizes":
            [[[150,
               82],
              "assets/images/resized/0005/0042/50042v2-max-150x150.png"],
             [[250,
               137],
              "assets/images/resized/0005/0042/50042v2-max-250x250.png"],
             [[308,
               169],
              "assets/images/resized/0005/0042/50042v2-max-450x450.png"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Venrock",
         "permalink": "venrock",
         "image":
          {"available_sizes":
            [[[150,
               52],
              "assets/images/resized/0001/6279/16279v1-max-150x150.jpg"],
             [[250,
               87],
              "assets/images/resized/0001/6279/16279v1-max-250x250.jpg"],
             [[351,
               123],
              "assets/images/resized/0001/6279/16279v1-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "MedImmune Ventures",
         "permalink": "medimmune-ventures",
         "image":
          {"available_sizes":
            [[[150,
               19],
              "assets/images/resized/0004/9449/49449v2-max-150x150.jpg"],
             [[250,
               31],
              "assets/images/resized/0004/9449/49449v2-max-250x250.jpg"],
             [[450,
               57],
              "assets/images/resized/0004/9449/49449v2-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Biogen Idec",
         "permalink": "biogen-idec",
         "image":
          {"available_sizes":
            [[[150,
               55],
              "assets/images/resized/0004/8826/48826v3-max-150x150.jpg"],
             [[206,
               76],
              "assets/images/resized/0004/8826/48826v3-max-250x250.jpg"],
             [[206,
               76],
              "assets/images/resized/0004/8826/48826v3-max-450x450.jpg"]],
           "attribution": null}},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Osage Venture Partners",
         "permalink": "osage-ventures",
         "image": null},
       "person": null},
      {"company": null,
       "financial_org":
        {"name": "Thomas, McNerney \u0026 Partners",
         "permalink": "thomas-mcnerney-partners",
         "image":
          {"available_sizes":
            [[[150,
               18],
              "assets/images/resized/0008/1733/81733v1-max-150x150.png"],
             [[250,
               30],
              "assets/images/resized/0008/1733/81733v1-max-250x250.png"],
             [[450,
               54],
              "assets/images/resized/0008/1733/81733v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "14 Cambridge Center",
    "address2": "Building 1",
    "zip_code": "02142",
    "city": "Cambridge",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}